Menu
Recruiting NCT06922344

Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor

Phase IV Interventional Pityriasis Versicolor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Fluconazole, Itraconazole.
Who it may be relevant to
Registry conditions: Pityriasis Versicolor. Basic parameters: 18 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Pakistan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.

Detailed description

Pityriasis versicolor is a common fungal infection of the superficial skin layers. Avalible treatment options include topical and systemic drugs. fluconazole and itraconazole are commonly used systemic agents. The aim of this study is to compare the efficacy of the two systemic drugs.

Interventions

  • Drug Fluconazole
    Oral fluconazole prescribed to group A
  • Drug Itraconazole
    Oral itraconazole prescribed to Group B

Primary outcome measures

  • Efficacy of Treatment [Time frame: Upto 8 weeks]

Eligibility criteria

Inclusion criteria

  • All cases of Pityriasis versicolor

Exclusion criteria

  • Patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities.
  • Patients who received any anti-fungal therapy in the last one month.
  • Pregnant or lactating women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Pakistan · 1 center
  • Khyber Teaching Hospital — Peshawar

Identifiers

NCT: NCT06922344 · 84/DME/KMC

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗